2024-03-28T15:55:49Zhttp://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/238572021-06-30T07:02:40Zcom_10324_23835com_10324_5186com_10324_29291col_10324_23837
UVaDOC
author
Rojo Martínez, Esther
editor
Ediciones Universidad de Valladolid
2017-06-20T17:39:49Z
2017-06-20T17:39:49Z
2014
Anales de la Real Academia de Medicina y Cirugía de Valladolid, 2014, N.51, pags.67-76
0210-6523
http://uvadoc.uva.es/handle/10324/23857
67
51
76
The progress made in recent years in research on Alzheimer's disease (AD) have necessitated a change in the diagnostic criteria of this disease. Therefore, in 2011 the new diagnostics for AD and mild cognitive impairment (MCI) due to Alzheimer criteria proposed by the National Institute on Aging and the Alzheimer's Association (NIA-AA) were published. These new criteria emphasize that the pathophysiological process of AD begins several years before the first clinical symptoms appear and propose the use of biomarkers able to predict progression to AD in preclinical stages, and to support the diagnosis in phases of MCI or dementia. Although most biomarkers currently are being used for research purposes, it is likely that in the near future are also available in clinical practice. The number of patients with EA continues to grow in a population such as ours increasingly aging; therefore, in this manner, these new criteria aim to make an early diagnosis of AD that allows establishing treatments capable of modifying the course of disease when available.
spa
Attribution-NonCommercial-NoDerivatives 4.0 International
Enfermedad de alzheimer. Nuevos criterios diagnósticos e implicaciones en la práctica clínica.
info:eu-repo/semantics/article
URL
https://uvadoc.uva.es/bitstream/10324/23857/1/ARAMCV-2014-51-alzheimer-nuevos-criterios.pdf
File
MD5
32c072fd0482156e6718ef1fb938bc05
207645
application/pdf
ARAMCV-2014-51-alzheimer-nuevos-criterios.pdf